Efficacy and Safety of Inotuzumab Ozogamicin in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated in the INO-VATE Trial: Outcomes by Salvage-Treatment Phase

著录项

• 来源
  《Clinical lymphoma, myeloma & leukemia》 |2019年第1期|共1页
• 作者

  Jabbour Elias; Stelljes Matthias; Advani Anjali; DeAngelo Daniel; Goekbuget Nicola; Marks David; Stock Wendy; OBrien Susan; Cassaday Ryan; Wang Tao; Neuhof Alexander; Vandendries Erik; Kantarjian Hagop;

  展开▼
• 作者单位

  Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

  Univ Klinikum Munster Munster Germany;

  Cleveland Clin Taussig Canc Inst Cleveland OH 44106 USA;

  Dana Farber Canc Inst Boston MA 02115 USA;

  Goethe Univ Frankfurt Germany;

  Univ Hosp Bristol Bristol Avon England;

  Univ Chicago Chicago IL 60637 USA;

  Univ Calif Irvine Chao Family Comprehens Canc Ctr Orange CA 92668 USA;

  Univ Washington Sch Med Seattle WA USA;

  Pfizer Inc Groton CT 06340 USA;

  Pfizer Pharma GmbH Berlin Germany;

  Pfizer Inc Cambridge MA USA;

  Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词

  acute lymphoblastic leukemia; inotuzumab ozogamicin; salvage treatment; ALL;

  机译：急性淋巴细胞白血病;inotuzumab ozogamicin;抢救治疗;全部;